Patents by Inventor Prabha Ibrahim

Prabha Ibrahim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrazole-pyrimidines, variants thereof, and uses therefore
    Patent number: 11591315
    Abstract: Disclosed herein are substituted pyrazole-pyrimidine compounds of Formula I and variants thereof for the treatment, for example, of diseases associated with P2X purinergic receptors: In one embodiment, the P2X3 and/or P2X2/3 antagonists disclosed herein are potentially useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: February 28, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS
    Publication number: 20220347173
    Abstract: Disclosed herein are methods of treating liver fibrosis by administering calpain inhibitors to subjects in need thereof.
    Type: Application
    Filed: June 27, 2019
    Publication date: November 3, 2022
    Inventors: Sharlene Lim, Prabha Ibrahim, Maria Fuentes
  • CALPAIN INHIBITORS AND USES THEREOF FOR TREATING NEUROLOGICAL DISORDERS
    Publication number: 20220257570
    Abstract: Methods of treating neurological diseases and disorders associated with protein aggregation using calpain inhibitors are provided. Said neurological diseases associated with protein aggregation include polyglutamine expansion diseases such as Huntington's disease, Machado-Joseph disease, and spinocerebellar ataxias.
    Type: Application
    Filed: July 28, 2020
    Publication date: August 18, 2022
    Inventors: Prabha Ibrahim, Maria Fuentes, P. T. Ravi Rajagopalan, Walter Yu
  • Pyrimidines and variants thereof, and uses therefor
    Patent number: 11230532
    Abstract: The present disclosure provides pyrimidine compounds of Formula 1 and uses thereof, for example, for the potential treatment of diseases associated with P2X purinergic receptors: In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the potential treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: January 25, 2022
    Assignee: AFFERENT PHARMACEUTICALS, INC.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • Crystalline salts and polymorphs of a P2X3 antagonist
    Patent number: 11230533
    Abstract: Provided are novel salts and polymorphs of 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide, which are potentially useful for modulating a condition mediated by a P2X3 or P2X2/3 receptor. Also provided are pharmaceutical formulations and methods of administration and dosing of these salts and polymorphs to subjects in need thereof.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: January 25, 2022
    Assignee: AFFERENT PHARMACEUTICALS, INC.
    Inventors: Prabha Ibrahim, Ronald Charles Hawley, Anthony P. Ford, Steven A. Smith
  • USE OF BCL6 INHIBITORS FOR TREATING AUTOIMMUNE DISEASES
    Publication number: 20210330672
    Abstract: Described herein include compositions and methods that can be useful for inhibiting activity of Tfh cells, B-cells, germinal centers, extrafollicular T and B-cells, and/or ectopic follicular structures; and/or in treating diseases such as autoimmune diseases.
    Type: Application
    Filed: July 12, 2019
    Publication date: October 28, 2021
    Inventors: Michael FRANKEN, Stephen HALE, Richard GARMAN, Prabha IBRAHIM
  • VASCULAR ADHESION PROTEIN-1 (VAP-1) MODULATORS AND THERAPEUTIC USES THEREOF
    Publication number: 20210238192
    Abstract: Disclosed herein are small molecule Vascular Adhesion Protein-1 (VAP-1) modulator compositions, pharmaceutical compositions, the use and preparation thereof.
    Type: Application
    Filed: June 27, 2019
    Publication date: August 5, 2021
    Inventors: Brad Owen Buckman, Prabha Ibrahim, Shendong Yuan, Kumaraswamy Emayan, Marc Adler
  • SUBSTITUTED PYRAZOLE-PYRIMIDINES, VARIANTS THEREOF, AND USES THEREFORE
    Publication number: 20210171505
    Abstract: Disclosed herein are substituted pyrazole-pyrimidine compounds of Formula I and variants thereof for the treatment, for example, of diseases associated with P2X purinergic receptors: In one embodiment, the P2X3 and/or P2X2/3 antagonists disclosed herein are potentially useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Application
    Filed: February 19, 2021
    Publication date: June 10, 2021
    Applicant: Afferent Pharmaceuticals, Inc.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • Substituted pyrazole-pyrimidines, variants thereof, and uses therefore
    Patent number: 10988460
    Abstract: Disclosed herein are substituted pyrazole-pyrimidine compounds of Formula (I) and variants thereof for the treatment, for example, of diseases associated with P2X purinergic receptors. In one embodiment, the P2X3 and/or P2X2/3 antagonists disclosed herein are potentially useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: April 27, 2021
    Assignee: Afferent Pharmaceuticals, Inc.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • METHOD OF TREATING FIBROTIC DISEASE
    Publication number: 20210113560
    Abstract: Disclosed herein are methods of treating fibrotic disorders by administering compounds selective for CAPN1, CAPN2, and/or CAPN9 such that side effects, off pathway interactions, and/or toxicities are minimized Such methods may, for example, minimize unintended effects of therapeutic compounds by providing dosing and dosage forms that minimize the level of unbound drug within the relevant tissues of a patient undergoing treatment.
    Type: Application
    Filed: March 25, 2019
    Publication date: April 22, 2021
    Inventors: Brad Owen Buckman, Prabha Ibrahim, P T Ravi Rajagopalan
  • CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF
    Publication number: 20210009564
    Abstract: Small molecule calpain modulator compounds, including their pharmaceutically acceptable salts, can be included in pharmaceutical compositions. The compounds can be useful in inhibiting calpain, or competitive binding with calpastatin, by contacting them with CAPN1, CAPN2, and/or CAPN9 enzymes residing inside a subject. The compounds and composition can also be administered to a subject in order to treat a fibrotic disease or a secondary disease state or condition of a fibrotic disease.
    Type: Application
    Filed: March 21, 2019
    Publication date: January 14, 2021
    Inventors: Brad Owen Buckman, Shendong Yuan, Kumaraswamy Emayan, Marc Adler, Prabha Ibrahim
  • Pyrimidines and variants thereof, and uses therefor
    Patent number: 10822311
    Abstract: The present disclosure provides pyrimidine compounds and uses thereof, for example, for the treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: November 3, 2020
    Assignee: Afferent Pharmaceuticals, Inc.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • CRYSTALLINE SALTS AND POLYMORPHS OF A P2X3 ANTAGONIST
    Publication number: 20200255386
    Abstract: Provided are novel salts and polymorphs of 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide, which are potentially useful for modulating a condition mediated by a P2X3 or P2X2/3 receptor. Also provided are pharmaceutical formulations and methods of administration and dosing of these salts and polymorphs to subjects in need thereof.
    Type: Application
    Filed: April 30, 2020
    Publication date: August 13, 2020
    Applicant: Afferent Pharmaceuticals, Inc.
    Inventors: Prabha Ibrahim, Ronald Charles Hawley, Anthony P. Ford, Steven A. Smith
  • SUBSTITUTED PYRAZOLE-PYRIMIDINES, VARIANTS THEREOF, AND USES THEREFORE
    Publication number: 20200239451
    Abstract: Disclosed herein are substituted pyrazole-pyrimidine compounds of Formula (I) and variants thereof for the treatment, for example, of diseases associated with P2X purinergic receptors. In one embodiment, the P2X3 and/or P2X2/3 antagonists disclosed herein are potentially useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Application
    Filed: December 11, 2017
    Publication date: July 30, 2020
    Applicant: Afferent Pharmaceuticals, Inc.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR
    Publication number: 20200239421
    Abstract: The present disclosure provides pyrimidine compounds of Formula 1 and uses thereof, for example, for the potential treatment of diseases associated with P2X purinergic receptors: In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the potential treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Application
    Filed: April 13, 2020
    Publication date: July 30, 2020
    Applicant: Afferent Pharmaceuticals Inc.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • Crystalline salts and polymorphs of a P2X3 antagonist
    Patent number: 10676444
    Abstract: Provided are novel salts and polymorphs of 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide, which are potentially useful for modulating a condition mediated by a P2X3 or P2X2/3 receptor. Also provided are pharmaceutical formulations and methods of administration and dosing of these salts and polymorphs to subjects in need thereof.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: June 9, 2020
    Assignee: Afferent Pharmaceuticals, Inc.
    Inventors: Prabha Ibrahim, Ronald Charles Hawley, Anthony P. Ford, Steven A. Smith
  • Pyrimidines and variants thereof, and uses therefor
    Patent number: 10662162
    Abstract: The present disclosure provides pyrimidine compounds of Formula 1 and uses thereof for example, for the potential treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the potential treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: May 26, 2020
    Assignee: Afferent Pharmaceuticals, Inc.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • PYRIMIDINES AND VARIANTS THEREOF, AND USES THEREFOR
    Publication number: 20190389811
    Abstract: The present disclosure provides pyrimidine compounds and uses thereof, for example, for the treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.
    Type: Application
    Filed: March 9, 2017
    Publication date: December 26, 2019
    Applicant: Afferent Pharmaceuticals Inc.
    Inventors: Ronald Charles Hawley, Prabha Ibrahim, Anthony P. Ford, Joel R. Gever
  • CRYSTALLINE SALTS AND POLYMORPHS OF A P2X3 ANTAGONIST
    Publication number: 20190315698
    Abstract: Provided are novel salts and polymorphs of 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benzenesulfonamide, which are potentially useful for modulating a condition mediated by a P2X3 or P2X2/3 receptor. Also provided are pharmaceutical formulations and methods of administration and dosing of these salts and polymorphs to subjects in need thereof.
    Type: Application
    Filed: December 15, 2017
    Publication date: October 17, 2019
    Applicant: Afferent Pharmaceuticals, Inc.
    Inventors: Prabha Ibrahim, Ronald Charles Hawley, Anthony P. Ford, Steven A. Smith
  • Compounds and methods for kinase modulation, and indications therefor
    Patent number: 10227357
    Abstract: Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and mutant c-kit protein kinases.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: March 12, 2019
    Assignee: Plexxikon Inc.
    Inventors: Jack Lin, John Buell, Katrina Chan, Todd Ewing, Prabha Ibrahim, Marika Nespi, Phuongly Pham, Songyuan Shi, Wayne Spevak, Guoxian Wu, Jiazhong Zhang, Ying Zhang